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Abstract
Background: Multiple studies have demonstrated that rates of smoking and nicotine dependence are increased in
individuals with anxiety disorders. However, significant variability exists in the epidemiological literature exploring
this relationship, including study design (cross-sectional versus prospective), the population assessed (random
sample versus clinical population) and diagnostic instrument utilized.
Methods: We undertook a systematic review of population-based observational studies that utilized recognized
structured clinical diagnostic criteria (Diagnostic and Statistical Manual of Mental Disorders (DSM) or International
Classification of Diseases (ICD)) for anxiety disorder diagnosis to investigate the relationship between cigarette
smoking, nicotine dependence and anxiety disorders.
Results: In total, 47 studies met the predefined inclusion criteria, with 12 studies providing prospective information and
5 studies providing quasiprospective information. The available evidence suggests that some baseline anxiety disorders
are a risk factor for initiation of smoking and nicotine dependence, although the evidence is heterogeneous and many
studies did not control for the effect of comorbid substance use disorders. The identified evidence however appeared
to more consistently support cigarette smoking and nicotine dependence as being a risk factor for development of
some anxiety disorders (for example, panic disorder, generalized anxiety disorder), although these findings were not
replicated in all studies. A number of inconsistencies in the literature were identified.
Conclusions: Although many studies have demonstrated increased rates of smoking and nicotine dependence in
individuals with anxiety disorders, there is a limited and heterogeneous literature that has prospectively examined
this relationship in population studies using validated diagnostic criteria. The most consistent evidence supports
smoking and nicotine dependence as increasing the risk of panic disorder and generalized anxiety disorder. The
literature assessing anxiety disorders increasing smoking and nicotine dependence is inconsistent. Potential issues
with the current literature are discussed and directions for future research are suggested.
Keywords: agoraphobia, anxiety disorder, cigarette smoking, epidemiology, generalized anxiety disorder, nicotine
dependence, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, specific phobia
Background
Anxiety disorders (ADs) represent the most common
mental illness diagnoses across many countries [1,2] and
are associated with significant impairment to health and
quality of life [3,4]. Multiple population-based epidemio-
logical studies have identified increased rates of smoking
amongst individuals with mental illness, and increased
rates of mental illness amongst smokers [5]. Specifically,
ADs have been reported to be associated with increased
rates of smoking, increased consumption of cigarettes
per smoker, and lower rates of smoking cessation than
non-anxiety disordered control groups [6,7]. In addition,
increased anxiety symptoms as measured on symptom
scales appear to be correlated with increased rates of
smoking [8].
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The relationship between ADs, smoking behavior and
nicotine dependence (ND) could be explained by three
non-mutually exclusive relationships. Firstly, smoking
behavior and/or ND may increase the chances of devel-
oping an AD. Potential mechanisms underpinning this
include adverse effects of smoking on neurodevelopment
and neurotransmitter pathways modulating anxiety that
may predispose individuals to developing enhanced anxi-
ety, or direct effects to the respiratory and autonomic
systems that may alter physical responses to anxiety pro-
voking situations [9,10]. Secondly, ADs may increase
smoking behavior and the risk for ND. Mechanisms for
this could include a propensity for those with increased
anxiety to commence smoking, or use of cigarettes as an
anxiolytic self-treatment [11,12]. Thirdly, the relationship
may be underpinned by a shared vulnerability factor or
group of factors that increase the likelihood of smoking,
ND and AD development (for example, low socioeco-
nomic status) [2,13].
However, a number of inconsistencies exist within the
current literature examining the relationships between
cigarette smoking, ND and ADs. Firstly, many currently
available population-based epidemiological investigations
have utilized clinical symptom severity scales rather
than validated diagnostic instruments to make AD diag-
noses. Secondly, many studies utilizing validated diag-
nostic instruments have been cross-sectional, and
therefore unable to provide insight into the direction of
causality underpinning the association. Thirdly, many
investigations have been drawn from clinical populations
as opposed to whole population samples, potentially
introducing selection biases. An accurate assessment of
the association between cigarette smoking, ND and vali-
dated ADs, including direction of causality and potential
variation amongst differing anxiety disorder subgroups
or populations, may help inform targeted interventions
in at risk populations.
This paper aims to critically review the available epi-
demiological studies that have utilized general popula-
tion samples and validated diagnostic instruments based
upon recognized Diagnostic and Statistical Manual
(DSM) [14] or International Classification of Diseases
(ICD) systems [15], exploring the relationship between
cigarette smoking, ND and ADs. Structured diagnostic
instruments have advantages, as they are replicable
across studies, and in some cases include an interview
(for example, the Composite International Diagnostic
Interview (CIDI)). These interviews often document date
of onset and recent symptom expression, allowing for
assessments of temporality. A particular focus for this
review is on studies that have utilized prospective
designs and can therefore provide insight into the direc-
tion of the potential underlying causal relationships.
Methods
Systematic review search strategy
A systematic review of the English language literature
exploring relationships between ADs, ND and cigarette
smoking was undertaken. The aim was to provide a
descriptive overview of the available literature, with a
focus on information that could inform understanding
of direction of causality. A computerized search strategy
of medical databases PubMed and EMBASE utilized the
following search strategies, was limited to English lan-
guage literature and human studies. No date restrictions
were placed. PubMed: ‘Anxiety Disorders’ (MeSH) AND
(Smoking(Title/Abstract) OR Tobacco(Title/Abstract)
OR Nicotine(Title/Abstract) OR Cigarette(Title/
Abstract)) AND Anxiety AND (’humans’ (MeSH terms)
AND English); EMBASE: ‘#1 AND #2 AND #3’ where
#1 = ‘’anxiety disorder’/exp AND (humans)/lim AND
(english)/lim AND (embase)/lim’, #2 = ‘smoking:ab OR
tobacco:ab OR cigarette:ab OR nicotine:ab AND
(humans)/lim AND (english)/lim AND (embase)/lim’
and #3 = ‘’anxiety’/exp AND (humans)/lim AND (eng-
lish)/lim AND (embase)/lim’.
Extraction of references
All extracted references were combined and duplicate
references deleted. Titles and abstracts of all references
were initially assessed for relevance to the review topic.
Full texts of references identified as potentially contain-
ing relevant information were assessed against the pre-
determined inclusion criteria for quality and relevance.
For completeness, bibliographies of extracted references
were manually searched for further relevant references.
Where relevant references were discovered, their biblio-
graphies were manually searched.
Inclusion criteria
The following inclusion criteria were applied to the avail-
able references. Included studies needed to utilize a ran-
dom sample, drawn from the general population,
investigating the association between ADs, ND and cigar-
ette smoking. The included population must have been
assessed for panic disorder (PD), generalized anxiety dis-
order (GAD), obsessive-compulsive disorder (OCD),
social phobia (SP), specific phobia (SPP), post-traumatic-
stress disorder (PTSD) and/or agoraphobia (AG), utiliz-
ing a recognized and validated structured diagnostic tool
or documented clinician diagnosis in line with either
ICD-9/ICD-10 or DSM-III or DSM-IV criteria. The cri-
teria establishing cigarette smoking must have been
clearly documented, either as dichotomous (yes/no) or
through frequency of cigarette consumption. ND must
have been diagnosed through a recognized diagnostic
tool linked to ICD or DSM criteria. The criteria for ND
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mirror those of other substance dependence disorders,
and include (amongst others) symptoms of tolerance,
withdrawal, increasing use and difficulty quitting. All
data must have represented new information and not
replication of previous study results.
Literature search and application of inclusion criteria
The structured computerized literature search was per-
formed on 18 November 2011 yielded 298 references from
PubMed and 138 references from EMBASE. In all, 36
records were duplicated after compilation of search
results, leaving 400 unique records. Initial review of titles
and abstracts revealed 91 records with potentially relevant
information for the review. Manual searching of the biblio-
graphies from these 91 references revealed 16 further
potential references. Full text review of these 107 refer-
ences revealed 47 studies meeting the inclusion criteria.
See Figure 1 for search strategy flowchart and Figure 2 for
breakdown of studies.
Data extraction
All data were extracted upon the following variables: (1)
study name, (2) study population, (3) study design (pro-
spective, quasiprospective or cross-sectional), (4) definition
of AD diagnosis, (5) definition of smoking status, (6) statis-
tical parameters utilized and (7) primary results presented.
A focus on measures of association (for example, odds
ratio (OR), hazard ratio (HR)) was taken. Where available,
both unadjusted and adjusted measures were extracted.
Data were extracted into a preprepared structured Micro-
soft Excel database (Microsoft; Redmond, WA, USA).
Results
There were 47 studies meeting inclusion criteria. The stu-
dies were broken down by type and direction of analysis
(prospective, quasiprospective and cross-sectional) and are
represented in Additional files 1, 2, 3, 4, 5.
Prospective studies
A total of 13 studies were identified that utilized popula-
tion-based samples to assess a prospective relationship
between ADs, smoking behavior, and ND. These studies
comprised random population samples drawn from the
United States, New Zealand, Germany and The Nether-
lands, with some samples used in multiple studies. Discus-
sion of the included studies has been grouped below based
on the sample used.
Influence of anxiety disorders on risk of later smoking or
nicotine dependence
(A summary of this section is as follows (see also Addi-
tional file 1, Table S1): the best available evidence is equi-
vocal, but suggests that certain baseline ADs are risk
factors for onset of smoking and nicotine dependence,
although results vary across studies and across different
disorders. The best available studies failed to control for
comorbid substance use disorders.)
The first published prospective data were drawn from
the Oregon Adolescent Project Depression project, which
randomly recruited adolescents (aged 14 years to 18 years)
from high schools in Western Oregon, USA in 1987 to
1989 and followed them at two time points (1 year later,
and on their 24th birthday). Assessment of ADs was
undertaken utilizing the Schedule for Affective Disorders
and Schizophrenia for School-Age Children (K-SADS) for
DSM-III revision (DSM-III-R) [16], and smokers were
defined as those smoking ≥ 3 times per week. Brown et al.
[17] demonstrated no difference in the odds for incident
smoking at 1-year follow-up in those with versus without
any ADs at baseline, both unadjusted and after controlling
for a variety of demographic and other risk factors. This
finding of no association was replicated in the 24-year-old
follow-up [18] although only PD, and not grouped ADs,
was used as the exposure variable.
Breslau et al. [19] utilized a random population sample
of 1,007 young adults (21 years to 30 years), drawn from
the Detroit Epidemiologic Study, to examine PD as a pre-
dictor of cigarette smoking. Baseline assessment occurred
in 1989 and three follow-ups (1990, 1992 and 1994) were
conducted. Diagnosis of PD was made through use of the
National Institute of Mental Health Diagnostic Interview
Schedule [20] for DSM-III-R criteria, and ‘daily smoking’
was defined as smoking daily for ≥ 1 month. Risk of smok-
ing onset was increased in those with PD at baseline (HR
= 2.20 (95% CI 1.10 to 4.42)), but this significance was lost
when controlled for the presence of major depressive dis-
order (MDD). Breslau et al. [21] extended their investiga-
tion, incorporating two further follow-ups (1999 and
2001) to assess the interaction between PTSD and ND
over 10 years. After adjusting for gender, race and educa-
tion, the odds of incident ND at follow-up was 4.03 (95%
CI 2.10 to 7.72) in those with baseline PTSD versus those
without a trauma history.
Johnson et al. [22] followed a random sample of adoles-
cents from New York state, assessed at baseline in 1983
(mean age 14 years) and at two subsequent follow-ups in
1985 to 1986 (mean age 16 years) and 1991 to 1993 (mean
age 22 years). Diagnosis of ADs (grouped and individual)
at baseline was made using the Diagnostic Interview Sche-
dule for Children (DIS-C) [23] to DSM-III criteria. Smok-
ing assessment was by self-report, and categorized into
smoking > 1 pack (20+ cigarettes) versus smoking < 1
pack (1 to 19 cigarettes) per day (not non-smokers). After
adjusting for a variety of demographic and other risk
factors no association was detected between adolescent
anxiety disorder status and onset of smoking in adulthood.
The Early Developmental Stages of Psychopathology
(EDSP) study has been utilized to assess the association
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between ADs, ND and smoking behavior. In this study, a
random community cohort of 3,021 adolescents and
young adults (age 14 years to 24 years) was sampled from
metropolitan Munich. The cohort was assessed at baseline
(1995) and two follow-ups, the first between 1996 and
1997 and the second between 1998 and 1999 (a third fol-
low-up was subsequently conducted in 2005 to 2006) [24].
AD and ND diagnoses were made utilizing an updated
version [25] of the Composite International Diagnostic
Interview [26] for DSM-IV criteria and smoking was
assessed by self-report. Isensee et al. [27] categorized par-
ticipants from the EDSP into non-smokers, occasional
smokers, non-dependent regular smokers and dependent
regular smokers (see Additional file 1, Table S1 for defini-
tions) and calculated odds ratios for incident smoking by
baseline AD status. No associations were found between
baseline AD status and odds of incident smoking. Sonntag
et al. [28] extended this study in SP but once again found
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) search strategy flow diagram.
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no association, although a positive association was found
between those with social fears symptoms and later devel-
opment of ND.
Woodward et al. [29] utilized a New Zealand birth
cohort to compare the risk of DSM-IV ND between the
ages of 18 and 21, dependent upon diagnosis of ADs
between the ages of 14 to 16. A linear association was
found between increasing number of ADs at age 14 to
16 (0 to 3+) and subsequent ND diagnosis, although
this was not significant after controlling for childhood
sexual abuse, alcohol abuse, parental changes and devi-
ant peer affiliations.

*(+),".
%(' ",-"'%+,-"+4
"+$(+&($"' '
5%<6
*(+),".
%(' ",-"'%+,-"+4
"+$('0",1
"+(**+5%=6
-+"4*(+),".
%(' ",-"'%+,-"+4
"+$(+&($"' '
5%>6
-+"4*(+),".
%(' ",-"'%+,-"+4
"+$('0",1
"+(**+5%?6
*(+++,"('%
++(","('+5%@6
"*'(,%<DDA7?;8 "
"*'(,%3=;;;7>D8 "
*+%-,%3<DD<7?=8 "
*+%-<DD@7?<8 "
*+%-,%3<DDD7<D8 "! ! "! "
*+%-,%3=;;>7=<8 "
*+%-,%3=;;?7>C8 "!
*+%-,%3=;;?7>@8 "!
*(/',%3<DDA7<B8 ! !
**(%%,%3=;;D7?>8 "
!(-,%3=;<<7>;8 ! !
(+,%%(,%3<DDD7>B8 " "
(- %,%3=;<;7??8 "
-"#)*+,%3=;;B7>=8 " ! "
 '!*,,%3=;;<7?@8 "
"*$*,%3=;;B7?B8 "!
"*$*,%3=;;C7?A8 "!
-*",%=;<<7?C8 "
**%%,%3=;;>7?D8 "
%++&',%3<DD;7@;8 !
((/"',%3=;;@7<C8 ! !
*,%3=;;<7@<8 "
*',,%3=;;?7@=8 "
*',,%3=;;@7@>8 "
/1'',%3=;;C7@?8 "
	)$,%3=;;@7@@8 "

+'+,%3=;;>7=B8 ! ! "!
(!',%3=;;?7@A8 "
(!'+(',%3=;;;7==8 ! "
(!'+(',%3=;;D7>>8 !
'%,%3<DDB7@C8 "
'%,%3=;;<7@B8 "
('',%3=;;@7>A8 " "
++*,%3=;;;7@D8 "
/*',%3=;<;7A8 "
(**"+,%3=;;A7A;8 !
%+(',%3<DDC7A<8 "
)'%,%=;;=7A=8 "
!&",2,%3=;;>7A>8 
!-&'',%3=;;?7A?8 "!
('', ,%3=;;;7=C8 ! "!
/'+',%3=;<;7>?8 "!
("+,%3=;;C7B8 
+ 4()23=;;C7A@8 "!
",,!',%3<DDD7AA8 "
((/*,%3=;;<7=D8 "
-,%3=;<;7AB8 "
 " 		
"! 		

! 	
"	
 
 							 
! 			

 			
Figure 2 Included studies: prospective, quasiprospective and cross-sectional association information obtained from each study.
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Chou et al. [30] utilized the National Epidemiologic
Survey on Alcohol and Related Conditions (NESARC)
to investigate the association between ADs and ND in
adults age 60 years and older (n = 8,012). Diagnoses
were made utilizing the Alcohol Use Disorders and
Associated Disabilities Interview Schedule for DSM-IV
criteria (AUDADIS-IV) [31] and the risk of incident ND
was assessed between baseline (2000 to 2001) and fol-
low-up (2004 to 2005). No associations were found
between baseline AD status and subsequent ND.
Cuijpers et al. [32] utilized data from the Netherlands
Mental Health Survey and Incident Study (NEMESIS) to
investigate the relationship between incident ADs
(expressed as incident rate ratios) and previous smoking
status. The NEMESIS study randomly recruited adults
(18 years to 64 years) from 90 municipalities in The
Netherlands, undertaking baseline assessments and 2 fol-
low-ups at 1 year and 3 years (n = 4,796). The CIDI [26]
was used for DSM-III-R diagnoses, and smoking was
assessed by self-report, with participants placed into 4
categories (non-smokers, 1 to 9 cigarettes daily, 10 to 19
cigarettes daily and 20+ cigarettes daily). In a follow-up
analysis, having 12-month (incidence rate ratio (IRR)
4.46 (P < 0.05)) and lifetime GAD (IRR 4.46 (P < 0.05))
was associated with increased risk of smoking onset at
follow-up.
Johnson et al. [33] utilized the prospective follow-up of
the full NESARC database (n = 34,653) to assess the
impact of AD on smoking onset and persistence.
Grouped ADs were associated with reduced daily smok-
ing onset (OR 0.62 (95% CI 0.39 to 0.99)) when adjusting
for demographics and socioeconomic status, but not with
smoking persistence. Interestingly, comorbid substance
use was an effect modifier; respondents with a comorbid
substance use disorder (for example, alcohol, marijuana,
amphetamines, opioids, sedatives, tranquilizers, cocaine,
inhalants, hallucinogens, heroin, and other drugs) and
AD demonstrated an increased risk of daily smoking
onset (OR 2.22 (1.01 to 4.91)), whereas those without
comorbid substance use disorder had a decreased risk of
smoking onset (OR 0.43 (0.23 to 0.78)).
Most recently, Swendsen et al. [34] utilized a 10-year
follow-up of 5,001 participants drawn from the National
Co-morbidity Survey (NCS) to investigate mental disor-
ders as a risk factor for onset of daily smoking or ND. The
NCS, conducted in the US between 1990 and 1992, was a
stratified multistage probability sample of 8,098 non-
institutionalized residents (age 15 years to 54 years), utiliz-
ing the CIDI (V1.1), that assessed the interaction between
smoking, ND and DSM-III-R mental disorders. The
NCS2, performed in 2001 to 2002, was a 10-year re-inter-
view of 5,001 participants from the NCS, but which uti-
lized an updated version CIDI (V3.0) for DSM-IV criteria.
After adjusting for sociodemographic characteristics, the
odds of commencing daily smoking was increased for
respondents with baseline PD, SP, GAD and specific pho-
bia, but not for those with baseline PTSD or agoraphobia.
In contrast, in those respondents with baseline daily smok-
ing the odds of ND onset were raised in PTSD, agorapho-
bia and specific phobia, but not PD, SP or GAD. When
considering the whole population odds of ND onset, hav-
ing baseline PTSD, SP and specific phobia conferred an
increased risk (see Additional file 1, Table S1).
Smoking and nicotine dependence as risk factors for later
anxiety disorders
(A summary of this section is as follows (see also Addi-
tional file 2, Table S2): the available prospective evidence
associating smoking and nicotine dependence as risk fac-
tors for incident anxiety disorders is limited and hetero-
geneous. However, smoking has been demonstrated as a
risk factor for grouped anxiety disorders, panic disorder
and generalized anxiety disorder in a number of studies,
although these findings are not replicated in all studies.)
Data from the Oregon Adolescent Depression Project
were utilized to assess the relationship between baseline
smoking status and incident ADs. Goodwin et al. [18]
demonstrated an association between increased odds of
PD diagnosis at age 24 in those with daily smoking at
baseline versus those not smoking daily (OR 5.1 (2.4 to
10.5)), which remained significant after controlling for
other ADs and parental risk factors. No other associa-
tions were found.
Utilizing data from the Detroit Epidemiologic Study,
Breslau et al. [19] found increased risk of subsequent PD
onset in individuals with prior daily smoking even when
controlling for gender and MDD (HR 13.13 (4.41 to
39.10)). In addition, prior daily smokers who continued to
smoke were more likely to experience incident PD (HR
14.46 (4.81 to 43.5)) when controlled for gender and
MDD.
In the New York Adolescent Cohort, relationships
were discovered between odds of adult ADs when
grouped (OR 10.78 (1.48 to 78.55)), GAD (OR 5.53
(1.84 to 16.66) and PD (OR 15.58 (2.31 to 105.14) when
comparing baseline > 1 pack per day smokers versus < 1
pack per day smokers [22]. Data from the EDSP studies
[27] demonstrated relationships between increased inci-
dent PD, agoraphobia, SP and PTSD when comparing
baseline ND smokers versus non-users, however all
associations became non-significant when controlled for
comorbid conditions at baseline (depressive disorders,
panic attacks, other ADs, alcohol and drug disorders,
and eating disorders). In the NESARC study, Chou et al.
[30] assessed the relationship between ND at baseline
and subsequent ADs, finding no associations.
Cuijpers et al. [32] utilized data from the NEMESIS to
investigate the relationship between incident ADs
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(expressed as incident rate ratios) and past smoking sta-
tus. Smoking at 1-year follow-up was associated with
increased incidence of grouped ADs (IRR 1.77 (1.10 to
2.86)) and GAD (IRR 3.80 (1.09 to 13.21)) after control-
ling for demographics and other risk factors. No other
relationships were found (see Additional file 2, Table
S2).
Quasiprospective studies
(A summary of this section is as follows: a small number
of studies have utilized a single time point analysis and ret-
rospective self-report patient data to draw quasiprospec-
tive associations between smoking, ND and ADs. These
studies generally indicate increased smoking behaviors or
nicotine dependence in individuals with pre-existing anxi-
ety disorders, and vice versa, although studies are limited
by the retrospective nature of data.)
Baseline anxiety disorders and risk of smoking or
nicotine dependence
See also Additional file 3, Table S3. Breslau et al. [35]
examined the 4,411 participants who completed the
tobacco supplement of the NCS to assess the interaction
between smoking, ND and DSM-III-R ADs, utilizing dis-
crete time survival models with ADs as time dependent
variables and controlling for race, gender, education and
age. The onset of daily smoking was the age at which
respondents first smoked daily for ≥ 1 month. Increased
odds for daily smoking were found in patients with pre-
existing (OR 1.9 (1.05 to 3.7)) or currently active GAD
(OR 2.1 (1.1 to 3.9)), pre-existing (OR 1.6 (1.3 to 1.8)) or
currently active specific phobia (OR 1.5 (1.3 to 1.8)), pre-
existing (OR 1.5 (1.2 to 1.7)) or currently active SP (OR
1.3 (1.1 to 1.6)), and pre-existing (OR 2.1 (1.6 to 2.9)) or
currently active PTSD (OR 2.0 (1.4 to 2.9)).
Breslau et al. [35] further investigated the odds of smok-
ing persistence and the transitioning from daily smoking
to ND based upon pre-existing and currently active ADs.
Increased odds of transitioning from daily smoking to ND
were found in individuals with pre-existing and currently
active agoraphobia, specific phobia, SP and PTSD. Inter-
estingly, having pre-existing, but not currently active, PD
was also strongly associated with increased odds of daily
smoking to ND transition (OR 5.8 (3.0 to 11.6)). No asso-
ciations existed between odds of smoking persistence and
any pre-existing AD.
Koenen et al. [36] utilized data from the national Viet-
nam Era Twin (VET) registry and retrospective self-report
of age of onset to test prospective onset associations
between DSM-III-R ADs and ND. Associations were con-
trolled for various demographic and other risk factors and
time-dependent covariates (conduct disorder, MDD, alco-
hol and drug abuse or dependence) were entered into
models. The results demonstrated that pre-existing PTSD
was associated with increased odds of subsequent ND (OR
1.73 (1.38 to 2.17)). Utilizing the Greater Smoky Mountain
Study (GSMS), a longitudinal representative study of 4,500
children (aged 9 years, 11 years and 13 years) from
western North Carolina, USA, Costello et al. [37] found
children, both boys and girls, with any AD were more
likely to commence smoking than those without an AD
(see Additional file 3, Table S3).
Smoking and nicotine dependence and risk of incident
anxiety disorders
See also Additional file 4, Table S4. Breslau et al. [38] uti-
lized the NCS, including respondent recall about their
age of smoking and ND onset, to assess the effect of
these parameters on developing ADs. Adjusting for
demographic characteristics, pre-existing daily smoking
(defined as onset > 1 year prior to disorder onset) was
associated with increased odds of PD (OR 2.6 (1.2 to
5.4)) and agoraphobia (OR 4.4 (2.3 to 8.2)). The role of
ND was assessed across all ADs. In this analysis, ND
smokers and non-ND smokers maintained increased
odds of PD and agoraphobia, but no other ADs. The only
other associations were found in relation to past smokers
(without ND) who exhibited decreased odds of PTSD
(OR 0.2 (0.1 to 0.5)) when controlled for demographics
and other pre-existing psychiatric disorders. Breslau et al.
[38] extended their study by comparing the age of smok-
ing onset (early vs not early; see Additional file 4, Table
S4 for definitions), standardized pack years of smoking
and time since quitting against odds of AD diagnosis. No
association was found between early onset smoking and
ADs, but increased years since quitting was associated
with decreased odds of subsequent PD (OR 0.5 (0.4 to
0.7)), agoraphobia (OR 0.5 (0.5 to 0.8)) and SP (OR 0.6
(0.4 to 0.8)). The associations between standardized pack
years of smoking were not significant in all ADs except
PD, where increased pack years of smoking appeared
protective in current smokers but a risk factor in past
smokers, and GAD where increased pack years was asso-
ciated with increased odds of GAD in both current and
past smokers.
In a separate analysis utilizing a subsample of NCS data,
Breslau et al. [19] investigated the interaction between
smoking characteristics and subsequent onset of PD. Sig-
nificant relationships were discovered between prior daily
smoking (HR 2.93 (1.84 to 4.66)) and smoking persistence
in prior daily smokers (HR 3.18 (1.99 to 5.10)) and subse-
quent onset of PD. In addition, pre-existing ND was asso-
ciated with increased odds of subsequent PTSD onset (OR
2.24 (1.78 to 2.83)) in the aforementioned study drawn
from the VET registry [36].
Cross-sectional studies
(A summary of this section is as follows (see also Addi-
tional file 5, Table S5): a large number of studies have
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reported cross-sectional relationships between cigarette
smoking, nicotine dependence and anxiety disorders.
Many demonstrate higher rates of smoking and nicotine
dependence in those with anxiety disorders, and vice
versa. However, their utility is limited due to their inher-
ent inability to provide insight into direction of causality.)
Almost all studies included in this review reported
cross-sectional associations between smoking and/or
ND and ADs. Studies providing cross-sectional informa-
tion [6,7,17,19,23,27,28,32,39-67] are listed in Additional
file 5, Table S5. Descriptions of some selected larger
studies utilizing population-based data are detailed
below.
Smoking or nicotine dependence by anxiety disorder
status
Lasser et al. [59] utilized the NCS to demonstrate
increased rates of current and lifetime smoking in
respondents with current and lifetime SP (39.5% and
54%), agoraphobia (38.4% and 58.9%), PD (35.9% and
61.3%), specific phobia (40.3% and 57.8%), PTSD (45.3%
and 63.3%) and GAD (46% and 68.4%) when controlling
for gender, age and geographical region. Utilizing the
NCS-R data, Cougle et al. [44] explored the role of
comorbidity in the association between ADs and smoking
behavior. After controlling for demographics, depression
and drug abuse/dependence, associations between
increased odds of lifetime and 12-month daily smoking
were observed with PTSD (Lifetime: OR 1.58 (1.21 to
2.06); 12-month: OR 1.46 (1.08 to 1.97)), 12-month daily
smoking with PD (OR 1.42 (1.04 to 1.94)), and Lifetime
daily smoking with GAD (OR 1.23 (1.05 to 1.61)).
In a nationally representative sample of the New
Zealand population, individuals with ADs (grouped)
had a smoking prevalence of 30.4% (27.7 to 33.0), and
consumed approximately 16% of all cigarettes in New
Zealand [7]. In Australia, data from the nationally
representative National Survey of Mental Health and
Wellbeing 2007 reported rates of current and daily
smoking in those with individual ADs (range for cur-
rent smoker: 33% to 45%; range for daily smoker: 27%
to 42%) well above the rates in respondents not report-
ing a mental disorder (current: 13.6%; daily: 10.8%) [6].
Cougle et al. [44] demonstrated increased odds of ND
in patients with SP (OR 1.31 (1.01 to 1.71)), GAD (OR
1.59 (1.21 to 1.98)) and PTSD (OR 1.47 (1.01 to 2.16))
when adjusting for demographics, depression and drug
abuse/dependence. Utilizing the NESARC for adults
aged 18 to 25 years [46], the odds of 12-month ND
were significantly increased for respondents with life-
time specific phobia (OR 1.8 (1.16 to 2.88)) after con-
trolling for other psychiatric disorders, smoking and
demographic characteristics.
Anxiety disorder by smoking or nicotine dependence
status
Utilizing the German Transitions in Alcohol Consumption
and Smoking study, Schumann et al. [64] calculated unad-
justed odds ratios for individual ADs based on smoking
and ND status. When comparing ND ever smokers
(respondents with ND who had smoked at least one cigar-
ette daily for ≥ 4 weeks at some point in their life) to non-
ND ever smokers, increased odds were found for PD (OR
2.92 (1.78 to 2.73)), SP (OR 3.07 (1.70 to 5.57)), specific
phobia (OR 2.09 (1.63 to 2.68)), GAD (OR 4.26 (1.85 to
9.84)) and PTSD (OR 2.08 (1.13 to 3.83)). Grant et al. [52]
used data from NESARC to compare the odds of ADs on
ND status. Unadjusted odds ratios with individual ADs as
dependent variables were greater across all assessed ADs.
Point estimates for odds ratios ranged from 2.6 for SP to
4.6 for PD with agoraphobia for respondents with versus
without ND. Data from the UK National Households Sur-
vey [49] demonstrated increased rates of GAD (4.1% vs
2.4%), specific phobia (1.5% vs 0.8%) and PD (1.5% vs
0.5%) in respondents with ND versus those without ND.
Degenhardt et al. [45] utilized the 1997 National Survey of
Mental Health and Wellbeing in Australia to demonstrate
increased odds of ADs (grouped) in current smokers ver-
sus never smokers (OR 1.50 (1.21 to 1.87)) when adjusted
for demographic status, other drug use and neuroticism.
Discussion
Our systematic review of the literature revealed a total of
17 studies that provided prospective or quasiprospective
information regarding the relationship between ADs, ND
and cigarette smoking. Of these studies 14 provided pro-
spective or quasiprospective information on the role of
ADs on the risk of smoking or ND, and 7 studies provided
the role of daily smoking or ND on onset of ADs. A
further 31 studies reported only cross-sectional relation-
ships between smoking, ND and ADs. The association
between smoking, ND and ADs could be explained by
three non-mutually exclusive relationships; smoking and
ND leads to increased ADs, the reverse association, or a
shared vulnerability model where a factor or group of fac-
tors increase smoking, ND and AD expression.
Are anxiety disorders a risk factor for smoking onset?
A relatively common hypothesis links increased anxiety
with smoking onset and increased smoking behaviors.
Multiple studies conducted in both general and clinical
populations have demonstrated increased rates of smok-
ing amongst individuals with all AD subtypes [68-70],
although exceptions exist [71]. The results of these pro-
spective, quasiprospective and cross-sectional studies are
inconsistent, and importantly, many of these studies
have failed to take into account the important role of
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comorbid substance use disorders. In a study of patients
with ADs where those with alcohol and substance use
disorders were excluded, rates of smoking were lower
than the control population [72], indicating comorbid
illness is important in understanding this association.
This review found a limited and heterogeneous litera-
ture evaluating the prospective effect of ADs on smoking
onset in random population samples. The available data
varied significantly on population characteristics (whole
population vs specific age range), length of prospective
follow-up (1 year to 10 years), diagnostic tool utilized
and smoking definition. On balance, the 10-year follow-
up of the National Comorbidity Survey [34] represents
the likely best evidence available to date. From this analy-
sis, baseline PD, SP, GAD and specific phobia, but not
PTSD or agoraphobia, were associated with increased
odds of commencing daily smoking. There are however
important considerations in interpreting this study. First,
the diagnostic classification system utilized in the first
NCS (DSM-III-R) was updated in the NCS2 (DSM-IV).
Although there is a large concordance between these
diagnostic classifications across most ADs, some signifi-
cant differences exist, particularly in the criteria of PTSD,
which may have altered relative prevalence rates [73].
Second, and most importantly, the presented analyses did
not control for the presence of other psychiatric disor-
ders or for alcohol or drug abuse/dependence. As noted
by Cougle et al. [44], ADs are often comorbid disorders,
particularly with MDD and substance abuse disorders. In
other presented prospective studies, univariate relation-
ships between PD and smoking onset failed to sustain
significance when comorbid MDD was included in the
analytic models [19], and the presence of a comorbid
substance use disorder reversed the direction of effect of
baseline AD from protective to causative in the NESARC
cohort [33]. The NCS follow-up revealed larger increased
odds of daily smoking onset in respondents with alcohol
or other substance abuse/dependence (OR point esti-
mates between 2.6 and 4.2). As such, it is probable that
some of the association between ADs and smoking is due
to effects of comorbid substance abuse disorders.
Considering that most of the other available prospective
studies failed to find significant associations between ADs
and subsequent onset of smoking, it is currently difficult
to draw definitive conclusions regarding AD as a risk fac-
tor for smoking. One potential factor that should be taken
into account is the populations considered in the available
literature. Population-based studies suggest that the aver-
age age individuals first use cigarettes has been declining,
and now ranges between 12 years and 16 years [74]. In
addition, smokers who commence earlier are more likely
to persist than those that commence at a later age [75].
Given that most of the included studies assessed adult
populations, it is possible many participants with ADs
were already smoking and hence new onset smoking was
relatively rare in assessed populations. In contrast to
cross-sectional analyses, very limited prospective informa-
tion is available on varying characteristics of smoking
behavior (for example, persistence) and ADs in the avail-
able prospective studies.
Some studies have used a quasiprospective design, pair-
ing cross-sectional data with retrospective self-report data,
to assess the impact of ADs on smoking status. Such stra-
tegies are limited by recall bias, and any conclusions
drawn must consider this. Analysis of the NCS by Breslau
et al. [35] found increased odds of daily smoking in those
with a variety of pre-existing or current ADs. However,
these analyses did not control for the effects of comorbid
substance use disorders or other psychiatric disorders and,
additionally, were limited to onset of daily smoking as
opposed to smoking more generally. When considering
the effects of pre-existing ADs on smoking persistence, no
significant associations were found.
A number of theories are proposed to explain why ADs
may lead to increased rates of smoking. Theoretical expla-
nations are informed by both psychological (for example,
conditioning theory, cognitive theory, anxiety sensitivity
[76]) and biological (for example, nicotine effects and
withdrawal) factors. One explanatory model relates to the
use of cigarettes as an anxiolytic agent (that is, self-treat-
ment). Evidence supports that nicotine exposure does pro-
duce a subjective calming effect, although this is coupled
with an increase in objective measures of physiological
arousal [77]. Tachyphylaxis and homeostatic adjustment
however implies that acute and chronic effects of cigar-
ettes, as with any agents that induce tolerance and depen-
dence, may differ substantially. Treatment of this extensive
literature is beyond this review, although we refer readers
to a number of excellent comprehensive reviews on this
subject [78-81], which include identification of the metho-
dological challenges in exploring the effect of anxiety traits
and states on smoking behaviors.
Are anxiety disorders a risk factor for later nicotine
dependence?
Inconsistent although clearer associations between base-
line ADs and subsequent ND were found in the literature.
In the 10-year follow-up of the NCS [34], having baseline
PTSD, agoraphobia and specific phobia were associated
with increased odds of onset of ND amongst already smo-
kers, and PTSD, SP and specific phobia were associated
with increased odds for ND amongst the whole popula-
tion. The clear association between baseline PTSD and
ND was replicated by Breslau et al. [21] in the Detroit
Epidemiologic Study, while Isensee et al. [27] found base-
line PD to be associated with increased risk for subsequent
ND. Given anxiety disorders are associated with negative
affect [82], and negative affect is linked to increased
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smoking motivation [83], it is possible that negative affect
may underpin an increased likelihood to developing ND in
those with ADs. Further evidence demonstrating an effect
of duration of anxiety disorder diagnosis and later ND
severity would be useful.
Is smoking or nicotine dependence a risk factor for
onset of anxiety disorders?
A limited number of prospective studies are available
assessing smoking or ND as risk factors for incident ADs
in population-based epidemiological studies. The avail-
able literature supports ND as increasing the odds of
later PTSD, and smoking as increasing the odds for some
(PD and GAD), but not all, ADs and interpretation of
some analyses are complicated by non-inclusion of
potential confounders. For example, the prospective odds
of PD onset were increased in the Oregon Adolescent
Depression Project, the New York Adolescent Cohort
and the EDSP in individuals with a history of prior smok-
ing versus non-smokers. This result remained significant
when controlling for other ADs in the Oregon Adoles-
cent Depression Study, but failed to maintain significance
when comorbid psychiatric disorders were controlled for
in the EDSP study. However, smoking as a risk factor for
PD is supported by the Detroit Epidemiologic Study,
which found increased risk of PD onset in prior daily
smokers, with a stronger association in prior daily smo-
kers who continued to smoke. These analyses controlled
for MDD, but not other psychiatric or substance use dis-
orders. The use of quasiprospective methodology on data
from the NCS allowed further exploration of this rela-
tionship. These data suggested that daily smoking was a
risk factor for increased odds of PD and agoraphobia,
with analyses controlling for other psychiatric disorders
including substance use disorders [38]. A demonstrated
dose-dependent relationship would support a causal
association between cigarette smoking and subsequent
onset of ADs. Breslau demonstrated that increased stan-
dardized pack years of smoking were associated with
increased odds of GAD, but decreased odds of PD [38] in
dose dependent fashion.
The interaction between panic, PD and cigarette smok-
ing has received more investigation in epidemiological
and laboratory-based studies than other ADs, and the
evidence was recently reviewed [84]. The literature has
demonstrated that earlier age of smoking initiation is
associated with increased risk of PD [85], and smokers
demonstrated earlier PD onset in comparison to non-
smokers [86]. Given the somatic nature of panic attack
symptomatology, it is possible that smoking may be more
likely to produce panic-type AD symptoms secondary to
the physical effects of smoking (for example, respiratory
and autonomic disturbance). Panic is influenced by
respiratory sensitivity, and nicotine alters the sensitivity
set point of cholinergic respiratory neurons [87]. From
their review of the literature, Cosci et al. [84] nominated
three potential hypotheses underpinning the association
between cigarette smoking and panic. The first is a ‘mod-
erational model’, whereby neuroticism moderates the
panic/smoking association. The second is a ‘pathoplastic
model’, where smoking influences PD expression by
‘exacerbating affective disturbances and negative health
process’ [88], including a combination of direct negative
health effects (for example, induction of chronic obstruc-
tive pulmonary disease (COPD)), acute physiological
effects (for example, increased noradrenaline and auto-
nomic sensations) and negative self-perception of health
status [89]. The third is the ‘false suffocation alarm’ the-
ory, proposed by Klein [90], who suggested that smoking
may induce hypersensitivity to suffocation signals and
increase the risk of experiencing panic. The suffocation
false alarm may potentially be mediated by episodic dys-
function in regulation of endogenous opioid function
[91].
A number of studies have assessed the interaction of
smoking and PTSD. A population-based follow-up investi-
gation of individuals affected by a fireworks factory explo-
sion in The Netherlands found that those who were
smokers at time of traumatic incident had an increased
chance of experiencing severe anxiety symptoms (OR 2.32
(1.19 to 4.53)) and disaster related PTSD (OR 2.64 (1.05 to
6.62)) at 4-year follow-up, controlling for baseline symp-
toms, demographic characteristics and life events [92].
This supports the results of Koenen et al. [36], who
demonstrated that the presence of ND increased the risk
of developing PTSD in trauma exposed men (HR 1.98
(1.61 to 2.42)) and that shared genetic effects explained
63% of the ND-PTSD association. A number of neurobio-
logical (for example, alterations to the hypothalamic-pitui-
tary-adrenal axis, sympathetic nervous system
hyperactivity alteration to neurotransmitter system func-
tioning) and psychological factors may contribute to a
PTSD, ND and cigarette smoking association (see Fu et al.
[93] for review). ND may increase ADs by exacerbating
anxiety responses [94], or by facilitating other psychiatric
states (for example, depression) that may predispose indi-
viduals to develop anxiety. In addition, the number of ND
symptoms and nicotine withdrawal symptoms has been
robustly correlated in a dose-dependent fashion with
increasing anxiety disorder diagnosis [56]. In reference to
other ADs, supportive evidence was found for smoking
increasing the odds of developing GAD, while no evidence
was found to support smoking as a risk factor for onset of
SP, although some evidence supports the reverse associa-
tion in female ND smokers [28].
In assessing smoking or ND as a risk factor for ADs,
one factor that must be considered is that ADs have
been estimated to exhibit a median age of onset of only
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6 years [95]. Given the early age of AD development,
from early childhood through adolescence, exposure to
environmental cigarette smoke may influence AD devel-
opment. Exposure to second-hand smoke has been
demonstrated to be positively associated with symptoms
of GAD, but not PD in children and adolescents age 8
years to 15 years [96]. Additionally, early onset smoking
(10 to 15 years) has been associated with an earlier
onset of ADs when compared to late onset smoking (>
15 years) [97]. It is possible that exposure to cigarette
smoke in critical periods of brain development may be
one factor that predisposes individuals to subsequent
develop ADs. A number of biological pathways may
underpin this effect, including alteration in neurotrans-
mitter function, and induction of oxidative and nitrosa-
tive stress that may overwhelm intrinsic defenses
inhibiting normal neuronal cell functions, including neu-
roplasticity and neurogenesis.
Shared vulnerability between smoking, ND and ADs
A number of shared vulnerability factors contribute to
cigarette smoking behavior and ADs, including early child-
hood experiences and environment [83,98,99], problems
with impulsivity [100] and distress tolerance and neurotic
personality traits [101,102]. Indeed, it is possible that these
shared vulnerability factors are further underpinned by
other factors (for example, genetics, fetal insults), and ADs
and cigarette smoke could alter their expression (for
example, cigarette smoking may reinforce poor distress
tolerance). For a more detailed discussion of the role and
interaction of shared vulnerability factors see the review
by Morissette et al. [79].
Limitations and directions for future research
It is important to consider the limitations of this study
design in interpreting the results. This review was
designed deliberately to only consider random, large gen-
eral population samples where validated structured diag-
nostic tools were utilized to make diagnoses. Effort was
made to identify all studies meeting inclusion criteria,
although it is possible some important sources of infor-
mation were not identified, particularly from non-English
language journals. The inclusion criteria were designed
to allow for selection of only the best quality evidence
not restricted by certain biases (for example, selection
bias, recall bias) although as consequence of this a num-
ber of identified studies involving samples drawn from
clinic populations [72,103-105] and studies which utilized
anxiety symptom scores [8] or non-validated diagnostic
tools (for example, self-report) as end points were
excluded from final analysis. The heterogeneous nature
of included studies, particularly in regards to population
demographics; smoking definition; diagnostic criteria uti-
lized; diagnostic group included; and comorbid factors
included in analysis also complicates interpretation. A
number of future studies would assist in clarifying issues
from this review. First, the continuation of current pro-
spective cohorts over longer periods and the recruitment
of new cohorts, incorporating and measuring changes to
smoking behavior over time, would assist in clarifying the
relationship between smoking and ADs. Similarly, given
the early onset nature of many ADs, maternal and birth
cohorts assessing these issues would assist greatly in dee-
pening our understanding. Exploration of the effects of
quitting on anxiety and depression would also clarify
associations. In addition, further exploration of potential
biological mechanisms underpinning associated effects of
smoking and ADs would help to elucidate shared vulner-
abilities underpinning both ADs and smoking.
Conclusions
A large literature has demonstrated that individuals with
ADs have higher rates of smoking and ND than those
without ADs, although most extant information is drawn
from cross-sectional studies. In terms of prospective stu-
dies, there exists a limited heterogeneous literature exam-
ining the relationship between cigarette smoking, ND and
ADs in population-based epidemiological studies utilizing
structured diagnostic tools linked to ICD or DSM criteria.
The available prospective evidence provides support for
smoking and ND as being risk factors for the onset of PD
and GAD, although varied results are found across studies.
In addition, some ADs have been associated with subse-
quent onset of smoking and ND, although many studies
failed to include comorbid substance use disorders and
other psychiatric disorders in analyses.
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Additional file 3: Table S3. Quasiprospective studies investigating
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